English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/182523
Share/Impact:
Statistics
logo share SHARE   Add this article to your Mendeley library MendeleyBASE
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:

Title

Clinical characteristics of patients with central nervous system relapse in BCR-ABL1-positive acute lymphoblastic leukemia: the importance of characterizing ABL1 mutations in cerebrospinal fluid

AuthorsSánchez, Ricardo; Ayala, Rosa; Alonso, Rafael Alberto; Martínez, María Pilar; Ribera, Jordi; García, Olga ; Sánchez-Pina, José María; Mercadal, Santiago; Montesinos, Pau; Martino, Rodrigo; Barba, Pere; González-Campos, José A.; Barrios, Manuel; Lavilla, Esperanza; Gil, Cristina; Escoda, Lourdes; Abella, Eugènia; Amigo, M. Luz; Moreno, M. José; Bravo, Pilar; Guàrdia, Ramón; Hernández-Rivas, Jesús María; García-Guiñón, Antoni; Piernas, Sonia; Ribera, José María; Martínez-López, Joaquín
KeywordsNeoplasia
Acute lymphoblastic leukemia relapse
Central nervous system
Mutation analysis
BCR-ABL1
Issue DateJul-2017
PublisherSpringer Nature
CitationAnnals of Hematology 96(7): 1069-1075 (2017)
AbstractWe investigated the frequency, predictors, and evolution of acute lymphoblastic leukemia (ALL) in patients with CNS relapse and introduced a novel method for studying BCR-ABL1 protein variants in cDNA from bone marrow (BM) and cerebrospinal fluid (CSF) blast cells. A total of 128 patients were analyzed in two PETHEMA clinical trials. All achieved complete remission after imatinib treatment. Of these, 30 (23%) experienced a relapse after achieving complete remission, and 13 (10%) had an isolated CNS relapse or combined CNS and BM relapses. We compared the characteristics of patients with and without CNS relapse and further analyzed CSF and BM samples from two of the 13 patients with CNS relapse. In both patients, classical sequencing analysis of the kinase domain of BCR-ABL1 from the cDNA of CSF blasts revealed the pathogenic variant p.L387M. We also performed ultra-deep next-generation sequencing (NGS) in three samples from one of the relapsed patients. We did not find the mutation in the BM sample, but we did find it in CSF blasts with 45% of reads at the time of relapse. These data demonstrate the feasibility of detecting BCR-ABL1 mutations in CSF blasts by NGS and highlight the importance of monitoring clonal evolution over time.
Publisher version (URL)https://doi.org/10.1007/s00277-017-3002-1
URIhttp://hdl.handle.net/10261/182523
ISSN0939-5555
E-ISSN1432-0584
ISMN10.1007/s00277-017-3002-1
Appears in Collections:(IBIS) Artículos
Files in This Item:
File Description SizeFormat 
Sanchez2017_Article_ClinicalCharacteristicsOfPatie.pdf660,31 kBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.